Login to Your Account



Rasi Breaks EMA's Silence on Glybera, Transparency Issues

By Cormac Sheridan
Staff Writer

Wednesday, March 7, 2012
The month of May could prove to be an important milestone in the evolution of drug regulation in Europe. Around then, Amsterdam Molecular Therapeutics (AMT) Holding NV expects to hear a final decision from the European Medicines Agency (EMA) on its dossier for gene therapy treatment Glybera (alipogene tiparvovec), which has traced a highly circuitous route through various European Union institutions over the past couple of years.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription